{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:20:10Z","timestamp":1784125210318,"version":"3.55.0"},"reference-count":129,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}]},{"DOI":"10.13039\/501100003407","name":"Progetti di Rilevante Interesse Nazionale","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Progetti di Rilevante Interesse Nazionale","doi-asserted-by":"publisher","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Progetti di Rilevante Interesse Nazionale","doi-asserted-by":"publisher","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Progetti di Rilevante Interesse Nazionale","doi-asserted-by":"publisher","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the AGING Project\u2014Department of Excellence\u2014DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"the AGING Project\u2014Department of Excellence\u2014DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}]},{"name":"the AGING Project\u2014Department of Excellence\u2014DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}]},{"name":"the AGING Project\u2014Department of Excellence\u2014DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}]},{"DOI":"10.13039\/501100003196","name":"Ricerca Finalizzata 2018","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ricerca Finalizzata 2018","doi-asserted-by":"publisher","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ricerca Finalizzata 2018","doi-asserted-by":"publisher","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ricerca Finalizzata 2018","doi-asserted-by":"publisher","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AIL Novara Onlus, Novara, Italy","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"AIL Novara Onlus, Novara, Italy","award":["PRIN"],"award-info":[{"award-number":["PRIN"]}]},{"name":"AIL Novara Onlus, Novara, Italy","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}]},{"name":"AIL Novara Onlus, Novara, Italy","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Richter syndrome (RS) represents the occurrence of an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), in patients with chronic lymphocytic leukemia (CLL). Most cases of RS originate from the direct transformation of CLL, whereas 20% are de novo DLBCL arising as secondary malignancies. Multiple molecular mechanisms contribute to RS pathogenesis. B-cell receptor (BCR) overreactivity to multiple autoantigens is due to frequent stereotyped BCR configuration. Genetic lesions of TP53, CDKN2A, NOTCH1 and c-MYC deregulate DNA damage response, tumor suppression, apoptosis, cell cycle and proliferation. Hyperactivation of Akt and NOTCH1 signaling also plays a role. Altered expression of PD-1\/PD-L1 and of other immune checkpoints leads to RS resistance to cytotoxicity exerted by T-cells. The molecular features of RS provide vulnerabilities for therapy. Targeting BCR signaling with noncovalent BTK inhibitors shows encouraging results, as does the combination of BCL2 inhibitors with chemoimmunotherapy. The association of immune checkpoint inhibitors with BCL2 inhibitors and anti-CD20 monoclonal antibodies is explored in early phase clinical trials with promising results. The development of patient-derived xenograft mice models reveals new molecular targets for RS, exemplified by ROR1. Although RS still represents an unmet medical need, understanding its biology is opening new avenues for precision medicine therapy.<\/jats:p>","DOI":"10.3390\/cancers14194644","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T21:14:28Z","timestamp":1664140468000},"page":"4644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Richter Syndrome: From Molecular Pathogenesis to Druggable Targets"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-3268","authenticated-orcid":false,"given":"Samir","family":"Mouhssine","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"ref_1","first-page":"285","article-title":"Generalized Reticular Cell Sarcoma of Lymph Nodes Associated with Lymphatic Leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am. J. Pathol."},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised, International Agency for Research on Cancer. [Revised 4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"829983","DOI":"10.3389\/fonc.2022.829983","article-title":"Biology and Treatment of Richter Transformation","volume":"12","author":"Condoluci","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_8","first-page":"249","article-title":"Hodgkin Variant of Richter\u2019s Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review","volume":"15","author":"Gupta","year":"2021","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: Morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_10","unstructured":"(2022, September 07). Chronic Lymphocytic Leukemia-Cancer Stat Facts. Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4614-8051-8_8","article-title":"Richter syndrome","volume":"792","author":"Rossi","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10428194.2012.710327","article-title":"The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: Analysis of an intergroup trial (CALGB 9011)","volume":"54","author":"Solh","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.14132","article-title":"The morphology of CLL revisited: The clinical significance of prolymphocytes and correlations with prognostic\/molecular markers in the LRF CLL4 trial","volume":"174","author":"Oscier","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Robrecht","year":"2021","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): An analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12032-013-0800-8","article-title":"Hodgkin lymphoma transformation of chronic lymphocytic leukemia: Cases report and discussion","volume":"31","author":"Balcerzak","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: Biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/wdev.40","article-title":"Ink4-Arf locus in cancer and aging","volume":"1","author":"Sherr","year":"2012","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2018.00229","article-title":"NOTCH1 Aberrations in Chronic Lymphocytic Leukemia","volume":"8","author":"Rosati","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene\u2014The grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"Cerri","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.1038\/s41598-019-49390-9","article-title":"TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells","volume":"9","author":"Whillock","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","article-title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma","volume":"118","author":"Pisonero","year":"2011","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: Where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrm3274","article-title":"Understanding the language of Lys36 methylation at histone H3","volume":"13","author":"Wagner","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1073\/pnas.0900571106","article-title":"The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers","volume":"106","author":"Veeriah","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.17789","article-title":"Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target","volume":"195","author":"Gould","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2567.2012.03564.x","article-title":"B-cell receptor: From resting state to activate","volume":"136","author":"Treanor","year":"2012","journal-title":"Immunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"771454","DOI":"10.3389\/fonc.2021.771454","article-title":"Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin","volume":"11","author":"Gerousi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2013-02-486209","article-title":"Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","article-title":"Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8","volume":"125","author":"Gounari","year":"2015","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: Association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/cdd.2016.116","article-title":"Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets","volume":"24","author":"Norberg","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): A cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.18352","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/bjh.17971","article-title":"Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial","volume":"196","author":"Chiappella","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2013-10-534271","article-title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness","volume":"123","author":"Messina","year":"2014","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.880","article-title":"Richter syndrome: Molecular insights and clinical perspectives","volume":"27","author":"Rossi","year":"2009","journal-title":"Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11899-021-00645-1","article-title":"BTK Inhibitors in Chronic Lymphocytic Leukemia","volume":"16","author":"Gaballa","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1038\/bcj.2014.98","article-title":"Ibrutinib has some activity in Richter\u2019s syndrome","volume":"5","author":"Giri","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000477338","article-title":"Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant","volume":"10","author":"Master","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hon.2464","article-title":"Ibrutinib-induced rapid response in chemotherapy-refractory Richter\u2019s syndrome","volume":"36","author":"Fischer","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): Analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/hon.41_2880","article-title":"Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent BTK inhibitor in previously treated Richter transformation: Results from the phase 1\/2 BRUIN study","volume":"39","author":"Jurczak","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/S2152-2650(21)01746-8","article-title":"CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL\/SLL: Results from the Phase 1\/2 BRUIN Study","volume":"21","author":"Coombs","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40265-019-01163-4","article-title":"Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies","volume":"79","author":"Yalniz","year":"2019","journal-title":"Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17474086.2018.1456332","article-title":"Potential of BCL2 as a target for chronic lymphocytic leukemia treatment","volume":"11","author":"Moia","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results from the Full Population of a Phase II Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2021-154279","article-title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: The M. D. Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"ref_102","first-page":"785","article-title":"Hodgkin\u2019s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: A retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"929012","DOI":"10.3389\/fonc.2022.929012","article-title":"Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"917115","DOI":"10.3389\/fonc.2022.917115","article-title":"Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights","volume":"12","author":"Salvetti","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"680834","DOI":"10.3389\/fonc.2021.680834","article-title":"Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kipps, T.J. (2022). ROR1\u2014An Orphan Becomes Apparent. Blood, Online ahead of print.","DOI":"10.1182\/blood.2021014760"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ghaderi, A., Daneshmanesh, A.H., Moshfegh, A., Kokhaei, P., V\u00e5gberg, J., Schultz, J., Olin, T., Harrysson, S., Smedby, K.E., and Drakos, E. (2020). ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines, 8.","DOI":"10.3390\/biomedicines8060170"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2021-150280","article-title":"Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter\u2019s Syndrome","volume":"138","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjh.15440","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-0881-4","article-title":"Revolution of Chronic Lymphocytic Leukemia Therapy: The Chemo-Free Treatment Paradigm","volume":"22","author":"Scheffold","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach","volume":"102","author":"Koopmans","year":"2017","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.2020010187","article-title":"Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models","volume":"137","author":"Iannello","year":"2021","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.24762","article-title":"Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study","volume":"92","author":"Larsen","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","article-title":"Exportin 1 (Crm1p) is an essential nuclear export factor","volume":"90","author":"Stade","year":"1997","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","article-title":"Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Walker","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed\/Refractory Non Hodgkin\u2019s Lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14728222.2020.1832465","article-title":"Targeting p53 in chronic lymphocytic leukemia","volume":"24","author":"Moia","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2141.2004.05210.x","article-title":"Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion","volume":"127","author":"Nahi","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3324\/haematol.2018.206631","article-title":"Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells","volume":"104","author":"Ciardullo","year":"2019","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-136668","article-title":"Combined Genetic Lesions in TP53 and CDKN2A\/CDKN2B Drive B Cell Receptor-Dependent\/Costimulatory Signal-Independent Proliferation in Richter Syndrome","volume":"136","author":"Chakraborty","year":"2020","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:38:48Z","timestamp":1760143128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":129,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194644"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194644","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]}}}